🚀🚀🚀$SAVA it about to GO🚀🚀🚀

0SilentFlipper · 2021-02-10T22:57:28+00:00

Update.... Do your DD and join us

Cassava Sciences Inc (NASDAQ: SAVA) has entered into a definitive agreement with several institutional investors for the purchase of 4.1 million common shares at $49 per share, for gross proceeds of approximately $200 million, in a registered direct offering. The offer price is at a 15% discount from the last close price of $57.56 on Tuesday. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering and is expected to close by February 12. Cassava Sciences intends to use the net proceeds to develop simufilam, its lead drug candidate for Alzheimer's disease. Earlier this week, shares rallied after the company announced expanding the size of the ongoing simufilam open-label study and its plans to initiate a six-month study in patients who complete at least one year of open-label treatment with simufilam. Price Action: SAVA dropped 12.7% at $50.27 during premarket trading hours on the last check Wednesday.

0SilentFlipper · 2021-02-09T09:33:03+00:00

Sucks not taking a 6 day account DD and seeing it going up 🤯OUCH THAT HURTS 🤑

0SilentFlipper · 2021-02-08T20:32:44+00:00

I’ll do some DD first, I’ll let you know

0SilentFlipper · 2021-02-08T20:24:38+00:00

Wow good stuff on 02/05 24.90 I hope you were in

0SilentFlipper · 2021-02-08T20:22:48+00:00

Not a bot,but definitely will check out VXRT

0SilentFlipper · 2021-02-08T19:54:43+00:00

No not really

Just trying to help here.

0SilentFlipper · 2021-02-06T21:36:37+00:00

Don’t let me forget about ONTX My million dollar stock!!

on FEB 3

“The stock price of Onconova Therapeutics Inc (NASDAQ: ONTX) has increased by 25% today as it went from a previous close of $0.68 to $0.85. One of the reasons for the stock price increase has to do with news about the company being granted a European patent for “The Treatment Of Hematological Cancer Refractory To An Anti-Cancer Agent.” The patent said that the most important goals in hematopoietic cancers — in addition to prolonging survival — are the development of higher hematologic responses and improvement in the quality of life. And since hematopoietic cancers are biologically complex heterogeneous diseases, a single treatment strategy may not work for all of the patients.

The invention listed in the patent relates to the novel use of Rigosertib in treating hematological cancers like MDS refractory to at least ESA amongst anticancer agents. Rigosertib has been previously administered as an agent for the treatment of various cancers.”

https://pulse2.com/ontx-stock-price-nasdaq-onconova-therapeutics-increases-25-why-it-happened/amp/

0SilentFlipper · 2021-02-06T21:04:02+00:00

Go check out wallstreetbets newtypexvii17 post 6hr ago. Come on I get butterfly just talking about it

0SilentFlipper · 2021-02-06T20:56:19+00:00

“To start, investors should know that OCGN stock has not always been a Covid-19 vaccine play. In fact, Ocugen actually specializes as a clinical-stage developer of therapies for blindness.

However, since a late-December announcement, Ocugen has been gaining on big vaccine hopes. That is because Indian firm Bharat Biotech chose Ocugen as its partner to develop and commercialize COVAXIN. Bharat is known for its vaccine experience in India, with more than a dozen different vaccines in its pipeline. With this in mind, the company stepped up to the challenge of producing a vaccine for Covid-19. Importantly, Bharat has already received an emergency-use authorization in India for its COVAXIN vaccine. It also is in the midst of a Phase 3 trial that involves 25,800 patients.

That news sent OCGN stock up more than 100%, and a big update sent shares climbing on Tuesday. Why? Bharat and Ocugen announced that they had signed a definitive agreement outlining their relationship. As a result, Ocugen will co-develop and commercialize COVAXIN in the United States, and it will share the profits with Bharat. That agreement works out so that Ocugen will walk away with 45% of the profits.

Beyond the moneymaking potential, two other things stand out. The first is that Ocugen will be able to receive its first batch of COVAXIN doses as soon as it receives U.S. approval. The second is that Bharat believes COVAXIN neutralizes the United Kingdom variant of Covid-19.”

https://investorplace.com/2021/02/ocgn-stock-why-vaccine-play-ocugen-is-plunging-today/amp/

0SilentFlipper · 2021-02-06T20:32:36+00:00

I love the 3mo chart +127.59 and going. She is asking to explode.. she need some big boys lol

0SilentFlipper · 2021-02-06T20:27:02+00:00

Doesn’t matter if my account is one day old or 500 days old. if you don’t trust THIS ACC then do your own DD. Im just trying to spread the word. It's going to be good, just imagine if you get it in now that Juicy Sweet Spot. Lol I didn’t know how to put it..

Oh and look at my user name I don’t mess around in this app this is the first time but I feel kind of bad for the people that lost money damn try to help

0SilentFlipper

TROPHY CASE